Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Genotypes in matrix metalloproteinase 9 are a risk factor for COPD.

Tesfaigzi Y, Myers OB, Stidley CA, Schwalm K, Picchi M, Crowell RE, Gilliland FD, Belinsky SA.

Int J Chron Obstruct Pulmon Dis. 2006;1(3):267-78.

2.

Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population.

Haq I, Chappell S, Johnson SR, Lotya J, Daly L, Morgan K, Guetta-Baranes T, Roca J, Rabinovich R, Millar AB, Donnelly SC, Keatings V, MacNee W, Stolk J, Hiemstra PS, Miniati M, Monti S, O'Connor CM, Kalsheker N.

BMC Med Genet. 2010 Jan 15;11:7. doi: 10.1186/1471-2350-11-7.

3.

Matrix metalloproteinase gene polymorphisms: lack of association with chronic obstructive pulmonary disease in a Brazilian population.

Schirmer H, Basso da Silva L, Teixeira PJ, Moreira JS, Moreira AL, Simon D.

Genet Mol Res. 2009 Aug 25;8(3):1028-34. doi: 10.4238/vol8-3gmr596.

4.

Matrix Metalloproteinase-9 (279R/Q) Polymorphism is Associated with Clinical Severity and Airflow Limitation in Tunisian Patients with Chronic Obstructive Pulmonary Disease.

Bchir S, Nasr HB, Hakim IR, Anes AB, Yacoub S, Garrouch A, Benzarti M, Bauvois B, Tabka Z, Chahed K.

Mol Diagn Ther. 2015 Dec;19(6):375-87. doi: 10.1007/s40291-015-0163-2.

PMID:
26303146
5.

Polymorphisms in matrix metalloproteinase-1, -9 and -12 genes and the risk of chronic obstructive pulmonary disease in a Korean population.

Lee SY, Kim MJ, Kang HG, Yoo SS, Choi YY, Lee WK, Cha SI, Kim CH, Jung TH, Park JY.

Respiration. 2010;80(2):133-8. doi: 10.1159/000284926. Epub 2010 Feb 16.

6.

Gene-environment interaction between the MMP9 C-1562T promoter variant and cigarette smoke in the pathogenesis of chronic obstructive pulmonary disease.

Stankovic M, Kojic S, Djordjevic V, Tomovic A, Nagorni-Obradovic L, Petrovic-Stanojevic N, Mitic-Milikic M, Radojkovic D.

Environ Mol Mutagen. 2016 Jul;57(6):447-54. doi: 10.1002/em.22025. Epub 2016 Jun 7.

PMID:
27270564
7.

Matrix metalloproteinase-9 -1562C/T promoter polymorphism confers risk for COPD: a meta-analysis.

Chen L, Wang T, Liu L, Shen Y, Wan C, Wen F.

PLoS One. 2013;8(3):e60523. doi: 10.1371/journal.pone.0060523. Epub 2013 Mar 28.

8.

Analyses of association between PPAR gamma and EPHX1 polymorphisms and susceptibility to COPD in a Hungarian cohort, a case-control study.

Penyige A, Poliska S, Csanky E, Scholtz B, Dezso B, Schmelczer I, Kilty I, Takacs L, Nagy L.

BMC Med Genet. 2010 Nov 2;11:152. doi: 10.1186/1471-2350-11-152.

9.

Genetic polymorphisms of cytochrome p450 and matrix metalloproteinase in chronic obstructive pulmonary disease.

Cheng SL, Yu CJ, Yang PC.

Biochem Genet. 2009 Aug;47(7-8):591-601. doi: 10.1007/s10528-009-9252-4. Epub 2009 Jun 9.

PMID:
19507017
10.

Impact of Matrix Metalloproteinase 9 on COPD Development in Polish Patients: Genetic Polymorphism, Protein Level, and Their Relationship with Lung Function.

Gilowska I, Kasper Ł, Bogacz K, Szczegielniak J, Szymasek T, Kasper M, Czerwinski M, Sładek K, Majorczyk E.

Biomed Res Int. 2018 Dec 10;2018:6417415. doi: 10.1155/2018/6417415. eCollection 2018.

11.

MMP-9 genetic polymorphism may confer susceptibility to COPD.

Jiang S, Yang ZH, Chen YY, He Z, Zhou Y, Gao Y, Zhang Q, Tan MQ.

Genet Mol Res. 2016 Apr 25;15(2). doi: 10.4238/gmr.15026272.

12.

Genetic variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects.

Metzger IF, Luizon MR, Lacchini R, Tanus-Santos JE.

DNA Cell Biol. 2012 Apr;31(4):504-10. doi: 10.1089/dna.2011.1388. Epub 2011 Sep 21.

PMID:
21936677
13.

Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow.

Kang MJ, Oh YM, Lee JC, Kim DG, Park MJ, Lee MG, Hyun IG, Han SK, Shim YS, Jung KS.

J Korean Med Sci. 2003 Dec;18(6):821-7.

14.

[Study on matrix metalloproteinase 1, 9, 12 polymorphisms and susceptibility to chronic obstructive pulmonary disease among Han nationality in northern China].

Zhang RB, He QY, Yang RH, Lu BB, Liu YJ.

Zhonghua Liu Xing Bing Xue Za Zhi. 2005 Nov;26(11):907-10. Chinese.

PMID:
16676616
15.

MMP14 gene polymorphisms in chronic obstructive pulmonary disease.

Saitoh W, Sakamoto T, Hegab AE, Nomura A, Ishii Y, Morishima Y, Kai S, Iizuka T, Kiwamoto T, Matsuno Y, Massoud HH, Massoud HM, Hassanein KM, Sekizawa K.

Int J Mol Med. 2006 Apr;17(4):621-6.

PMID:
16525718
16.
17.

Genetic polymorphisms of matrix metalloproteinases and protein levels in chronic obstructive pulmonary disease in a Mexican population.

Hernández-Montoya J, Pérez-Ramos J, Montaño M, Ramírez-Venegas A, Sansores RH, Pérez-Rubio G, Velázquez-Uncal M, Camarena A, Ramos C, Falfán-Valencia R.

Biomark Med. 2015;9(10):979-88. doi: 10.2217/bmm.15.75. Epub 2015 Oct 6.

18.

Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema.

Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, Mishima M.

Am J Respir Crit Care Med. 2005 Dec 1;172(11):1378-82. Epub 2005 Aug 26.

PMID:
16126934
19.

Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes.

Masuko H, Sakamoto T, Kaneko Y, Iijima H, Naito T, Noguchi E, Hirota T, Tamari M, Hizawa N.

Int J Chron Obstruct Pulmon Dis. 2011;6:181-9. doi: 10.2147/COPD.S16383. Epub 2011 Mar 2.

20.

Association of glutathione-S-transferase omega haplotypes with susceptibility to chronic obstructive pulmonary disease.

Yanbaeva DG, Wouters EF, Dentener MA, Spruit MA, Reynaert NL.

Free Radic Res. 2009 Aug;43(8):738-43. doi: 10.1080/10715760903038440.

PMID:
19513904

Supplemental Content

Support Center